Ashish Deshmukh from the Medical University of South Carolina and colleagues analyzed mortality rates from cervical cancer in women under 25 in the United States from 1992 to 2021 and concluded that after the advent of human papillomavirus (HPV) vaccines, it began to decline rapidly. The publication about this appeared in the Journal of the American Medical Association. The first HPV vaccine was approved for routine use in the United States in 2006. At first, such drugs were available only to teenage girls, but gradually the range of indications for them expanded to include women under 45.
The researchers found that over the last 10 years examined, mortality has decreased by 62 percent. Between 2012 and 2019, it decreased by 12 percent annually to a total of 65 percent. In the 1990s, 50 to 60 American women under 25 died of cervical cancer every three years; in 2019–2021, there were 13 such cases. The authors of the study note that the progressive decline in mortality began after the introduction of HPV vaccines and there are no other factors to which it could be associated. At the same time, only about 60 percent of girls aged 13–15 have currently received the recommended doses of the vaccine in the United States.
